NO20073510L - Metoder, bestemmelser og preparater for behandling av retinolrelaterte sykdommer - Google Patents

Metoder, bestemmelser og preparater for behandling av retinolrelaterte sykdommer

Info

Publication number
NO20073510L
NO20073510L NO20073510A NO20073510A NO20073510L NO 20073510 L NO20073510 L NO 20073510L NO 20073510 A NO20073510 A NO 20073510A NO 20073510 A NO20073510 A NO 20073510A NO 20073510 L NO20073510 L NO 20073510L
Authority
NO
Norway
Prior art keywords
methods
retinol
treatment
related diseases
compositions
Prior art date
Application number
NO20073510A
Other languages
English (en)
Norwegian (no)
Inventor
Kenneth J Widder
Jay Lichter
Original Assignee
Sirion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirion Therapeutics Inc filed Critical Sirion Therapeutics Inc
Publication of NO20073510L publication Critical patent/NO20073510L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20073510A 2004-12-08 2007-07-06 Metoder, bestemmelser og preparater for behandling av retinolrelaterte sykdommer NO20073510L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US63444904P 2004-12-08 2004-12-08
US66092405P 2005-03-10 2005-03-10
US66090405P 2005-03-11 2005-03-11
US67240505P 2005-04-18 2005-04-18
US69851205P 2005-07-11 2005-07-11
PCT/US2005/044416 WO2006063128A2 (fr) 2004-12-08 2005-12-07 Procedes, dosages et compositions pour traiter des maladies liees au retinol

Publications (1)

Publication Number Publication Date
NO20073510L true NO20073510L (no) 2007-09-06

Family

ID=35735778

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20073510A NO20073510L (no) 2004-12-08 2007-07-06 Metoder, bestemmelser og preparater for behandling av retinolrelaterte sykdommer
NO20075018A NO20075018L (no) 2004-12-08 2007-10-04 Fremgangsmater, analyser og preparater for behandling av diabetes type I eller II

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20075018A NO20075018L (no) 2004-12-08 2007-10-04 Fremgangsmater, analyser og preparater for behandling av diabetes type I eller II

Country Status (18)

Country Link
US (3) US20060135460A1 (fr)
EP (3) EP1827407A4 (fr)
JP (3) JP4178281B2 (fr)
KR (2) KR100971695B1 (fr)
CN (3) CN101072555B (fr)
AU (3) AU2005314039B2 (fr)
BR (2) BRPI0520207A2 (fr)
CA (2) CA2584845C (fr)
EA (2) EA010827B1 (fr)
GB (1) GB2421433B (fr)
GE (1) GEP20094644B (fr)
IL (2) IL182837A0 (fr)
LV (1) LV13666B (fr)
MX (1) MX2007006245A (fr)
NO (2) NO20073510L (fr)
NZ (2) NZ561148A (fr)
SG (1) SG144145A1 (fr)
WO (1) WO2006063128A2 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7553631B2 (en) 2003-12-11 2009-06-30 Beth Israel Deaconess Medical Center, Inc. RBP4 in insulin sensitivity/resistance, diabetes, and obesity
US7512436B2 (en) * 2004-02-12 2009-03-31 The Regents Of The University Of Michigan Method of evaluating metabolism of the eye
US20080176952A1 (en) * 2004-02-17 2008-07-24 Rando Robert R Management of Ophthalmologic Disorders, Including Macular Degeneration
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
KR101494067B1 (ko) 2004-03-05 2015-02-16 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
PL1768657T3 (pl) 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
JP2008519054A (ja) * 2004-11-04 2008-06-05 シリオン セラピューティクス， インコーポレイテッド レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター
CA2584845C (fr) * 2004-12-08 2009-02-17 Sirion Therapeutics, Inc. Procedes, dosages et compositions pour traiter des maladies liees au retinol
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
AU2006304689A1 (en) * 2005-10-18 2007-04-26 Aegerion Pharmaceuticals Compositions for lowering serum cholesterol and/or triglycerides
US20090042835A1 (en) * 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
JP2010513534A (ja) * 2006-12-21 2010-04-30 エージェリオン ファーマシューティカルズ， インコーポレイテッド Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
CA2681850C (fr) * 2007-04-20 2013-07-23 Acucela Inc. Composes derives de styrenyle pour traiter des maladies et des troubles ophtalmiques
RU2470910C9 (ru) 2007-06-29 2013-05-20 Акьюсела, Инк. Соединения, представляющие собой алкинилфенильные производные, для лечения офтальмических заболеваний и расстройств
WO2009035673A1 (fr) * 2007-09-12 2009-03-19 Trustees Of Columbia University In The City Of Newyork Compositions et procédés de traitement de la dégénérescence maculaire
MY156662A (en) 2007-11-01 2016-03-15 Acucela Inc Amine derivative compounds for treating ophthalmic diseases and disorders
CN101452001B (zh) * 2007-12-06 2013-07-24 王颖 化学发光磁酶免疫法定量检测rbp4试剂盒
WO2009089380A2 (fr) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Procédés pour la régulation médiée par p2ry5 de la pousse de cheveux et des mutants de ceux-ci
CA2724023C (fr) * 2008-05-13 2014-02-18 Genmedica Therapeutics Sl Conjugues de salicyles utiles pour le traitement de troubles metaboliques
CN101307314B (zh) * 2008-07-04 2011-12-14 中国医学科学院医学生物学研究所 重组噬菌体rbp/t7的构建及用其制备2型糖尿病疫苗的方法
EP2331971A1 (fr) 2008-10-09 2011-06-15 Merck Patent GmbH Marqueurs génétiques de type strogènes et anti- strogènes
MX360460B (es) 2008-10-20 2018-11-05 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion de transtiretina.
WO2010085514A1 (fr) * 2009-01-22 2010-07-29 Celladon Corporation Dosages de transfert d'énergie par résonance de fluorescence pour une atpase calcique de sarco/réticulum endoplasmique et phospholamban
JP2012520342A (ja) * 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
US20100239552A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination Therapies for Treating Metabolic Disorders
US20120108665A1 (en) * 2009-05-04 2012-05-03 Revision Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions
US9101643B2 (en) 2009-11-03 2015-08-11 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
AU2015264811A1 (en) * 2010-03-29 2016-01-07 Alnylam Pharmaceuticals, Inc. SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
AU2011235276B2 (en) * 2010-03-29 2015-09-03 Alnylam Pharmaceuticals, Inc. SiRNA therapy for transthyretin (TTR) related ocular amyloidosis
JP5951625B2 (ja) 2010-11-24 2016-07-13 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ 加齢性黄斑変性症およびシュタルガルト病の処置のための非レチノイドｒｂｐ４アンタゴニスト
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
CA2835215C (fr) 2011-05-18 2023-10-10 The Regents Of The University Of California Compositions de cellule retienne humaine non-immortelle, leur methode depreparation et leur utilisation pour le traitement de maladies retiniennes
EP3730618A1 (fr) 2011-11-18 2020-10-28 Alnylam Pharmaceuticals, Inc. Agents d'arni, compositions et procédés d'utilisation correspondants pour traiter des maladies associées à la transthyrétine (ttr)
WO2013166041A1 (fr) * 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Ligands de la transthyrétine pouvant inhiber l'interaction de rbp4-ttr dépendante du rétinol pour le traitement de la dégénérescence maculaire liée à l'âge, de la maladie de stargardt et d'autres maladies de la rétine caractérisées par une accumulation excessive de lipofuscine
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9790269B2 (en) 2013-02-08 2017-10-17 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US10092393B2 (en) 2013-03-14 2018-10-09 Allotex, Inc. Corneal implant systems and methods
EP3495357B1 (fr) 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phénylpipéridines, leur préparation et leur utilisation
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
WO2014152018A1 (fr) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, leur préparation et leur utilisation
CN104774840B (zh) * 2014-01-10 2019-09-17 中国人民解放军第三军医大学第一附属医院 基因突变体及其应用
SG11201608943VA (en) 2014-04-30 2016-11-29 Univ Columbia Substituted 4-phenylpiperidines, their preparaiton and use
CN113599539A (zh) 2014-08-29 2021-11-05 阿尔尼拉姆医药品有限公司 治疗甲状腺素运载蛋白（ttr）介导的淀粉样变性的方法
JP2017538728A (ja) * 2014-12-19 2017-12-28 ケミン、インダストリーズ、インコーポレーテッドＫｅｍｉｎ Ｉｎｄｕｓｔｒｉｅｓ， Ｉｎｃ． イオントフォレシスを用いた生物活性分子の眼内送達
WO2016160718A1 (fr) 2015-03-27 2016-10-06 University Of Washington Méthodes de traitement des maladies rétiniennes par modulation de l'expression génétique des photorécepteurs
PT3329002T (pt) 2015-07-31 2021-01-12 Alnylam Pharmaceuticals Inc Composições de iarn de transtirretina (ttr) e métodos de seu uso para tratamento ou prevenção de doenças associadas à ttr
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
BR112018071559B1 (pt) * 2016-04-22 2024-02-06 Viking Therapeutics, Inc Uso de um agonista de receptor beta de hormônios da tireoide para o tratamento de adrenoleucodistrofia ligada ao x
AU2017252126B2 (en) 2016-04-22 2023-02-09 Metabasis Therapeutics, Inc. Use of thyroid beta-agonists
KR20190020661A (ko) 2016-04-28 2019-03-04 스파크 테라퓨틱스, 인코포레이티드 아이소메로하이드롤라아제를 인코딩하는 바이러스 벡터에 대한 상대 효능 검정
GB201706009D0 (en) * 2017-04-13 2017-05-31 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of stargardt disease
BR112020005230A2 (pt) 2017-09-19 2020-09-24 Alnylam Pharmaceuticals, Inc. composições e métodos para o tratamento da amiloidose mediada por transtiretina (ttr)
EP3709990A4 (fr) * 2017-11-17 2021-12-01 The Regents of the University of California Manipulation de la voie de signalisation de l'acide rétinoïque
US20220184102A1 (en) * 2019-03-27 2022-06-16 University Of Virginia Patent Foundation Compositions and methods for treating age-related macular degeneration
KR102266963B1 (ko) * 2019-12-12 2021-06-18 연세대학교 산학협력단 렙틴 및 카로티노이드 관련 대사체, 및 피하지방면적을 이용한 식이 제한 후 비만의 대사적 상태를 예측하는 방법
CN112043820B (zh) * 2020-09-16 2022-06-21 易舟(上海)生物医药有限公司 一种眼用制剂及其制备方法和应用
CA3186856A1 (fr) 2020-07-29 2022-02-03 Ruth NALLEN Lomitapide destine a etre utilise dans des methodes de traitement de l'hyperlipidemie et de l'hypercholesterolemie chez des patients pediatriques
CA3227852A1 (fr) 2021-08-03 2023-02-09 Alnylam Pharmaceuticals, Inc. Compositions d'arni de la transthyretine (ttr) et leurs procedes d'utilisation
CN116570724A (zh) * 2023-05-17 2023-08-11 四川大学 一种基于肿瘤微环境激活型高尔基体靶向干扰剂的纳米粒

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US529455A (en) 1893-10-14 1894-11-20 Detachably securing gun-barrels to stocks
USRE29169E (en) 1971-02-10 1977-04-05 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
US4474878A (en) 1975-09-29 1984-10-02 Cordis Laboratories, Inc. Sandwich EIA for antigen associated with hepatitis
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4310546A (en) 1978-07-31 1982-01-12 Johnson & Johnson Novel retinoids and their use in preventing carcinogenesis
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4618485A (en) 1982-03-12 1986-10-21 International Immunoassay Laboratories, Inc. Kinetic radioimmunoassay test method and device
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4665098A (en) * 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4743400A (en) 1986-09-22 1988-05-10 Mcneilab, Inc. Process for preparing retinoyl chlorides
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5814612A (en) * 1991-04-09 1998-09-29 Sloan-Kettering Institute For Cancer Research Retinol derivatives and uses thereof
US6506917B1 (en) * 1991-12-18 2003-01-14 The Salk Institute For Biological Studies Compounds and compositions useful for modulation of processes mediated by RXR
US5591646A (en) 1992-09-02 1997-01-07 Arris Pharmaceutical Method and apparatus for peptide synthesis and screening
US5389681A (en) * 1992-10-22 1995-02-14 Ciba-Geigy Corporation Parenteral solutions for diclofenac salts
WO1994011030A1 (fr) 1992-11-13 1994-05-26 The Ohio State University Research Foundation Analogues arylamide de n-(4-hydroxyphenyl)retinamide-o-glucuronide
US5314909A (en) * 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
CA2184356A1 (fr) 1994-03-03 1995-09-08 Russell P. Rother Genes et proteines de fusion inhibant le complement terminal
DE69533921T2 (de) 1994-03-23 2005-12-01 Alexion Pharmaceuticals, Inc., New Haven Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs
US5427571A (en) * 1994-08-08 1995-06-27 Cor-A-Vent Incorporated Ventilated cap system for the ridge of a roof
JPH08136546A (ja) 1994-11-15 1996-05-31 Bio Sensor Kenkyusho:Kk 物質分析法
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
US5843884A (en) 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US5866341A (en) 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US5846220A (en) * 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
US6034211A (en) * 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
AU5727798A (en) * 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
US5955305A (en) * 1997-04-28 1999-09-21 Incyte Pharmaceuticals, Inc. Human retinoid binding protein
US5776915A (en) * 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
DE69840126D1 (de) * 1997-08-15 2008-11-27 Univ Duke Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
US6100090A (en) 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
EP1153248B1 (fr) * 1998-12-17 2006-04-19 Diversi-Plast Products Inc. Event a chapeau de faitage
US6343257B1 (en) 1999-04-23 2002-01-29 Peptor Ltd. Identifying pharmacophore containing combinations of scaffold molecules and substituents from a virtual library
US6128870A (en) * 1999-05-24 2000-10-10 Kohler; Raymond L. Roof vent system
AU7586600A (en) * 1999-09-14 2001-04-17 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
CA2392453C (fr) * 1999-11-23 2012-03-20 Gerhart Graupner Modulation de transduction de signal
US6450882B1 (en) * 2000-08-30 2002-09-17 Liberty Diversified Industries, Inc. Precipitation resistant ridge vent
US20020031539A1 (en) * 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
US20030032078A1 (en) * 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
ATE445589T1 (de) * 2001-05-29 2009-10-15 Chebigen Co Ltd Neue retinoidderivate und eine pharmazeutische anti-krebs-zusammensetzung, die diese verbindungen enthält
CA2450562A1 (fr) * 2001-06-22 2003-01-03 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
WO2003007944A1 (fr) * 2001-07-20 2003-01-30 Qlt, Inc. Traitement d'oedemes maculaires par therapie photodynamique
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US20040014131A1 (en) * 2002-07-09 2004-01-22 Pfizer Inc. Assay methods
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
CA2509955A1 (fr) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations utiles pour lutter contre les infections par le virus de l'hepatite c
FI20030426L (fi) * 2003-03-24 2004-09-25 Tomi Jaervinen Syklodekstriinikompleksit
US7553631B2 (en) * 2003-12-11 2009-06-30 Beth Israel Deaconess Medical Center, Inc. RBP4 in insulin sensitivity/resistance, diabetes, and obesity
US7566808B2 (en) * 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CA2601278C (fr) * 2004-03-17 2014-06-10 Lars Michael Larsen Prevention de la retinopathie par inhibition du cycle visuel
NZ587006A (en) * 2004-06-18 2011-12-22 Univ Washington 11-cis-Retinal derivatives and methods for the use thereof for the treatment of visual disorders
PL1768657T3 (pl) * 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
US20080033053A1 (en) * 2004-07-22 2008-02-07 Wolfgang Curt D Cross-Reference To Related Applications
AU2005287343A1 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
JP2008519054A (ja) * 2004-11-04 2008-06-05 シリオン セラピューティクス， インコーポレイテッド レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター
CA2584845C (fr) * 2004-12-08 2009-02-17 Sirion Therapeutics, Inc. Procedes, dosages et compositions pour traiter des maladies liees au retinol
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding

Also Published As

Publication number Publication date
CA2584845C (fr) 2009-02-17
EP1930046A1 (fr) 2008-06-11
SG144145A1 (en) 2008-07-29
AU2005314039B2 (en) 2008-01-31
US20060135460A1 (en) 2006-06-22
CN102240278A (zh) 2011-11-16
EA200701828A1 (ru) 2008-02-28
KR100971695B1 (ko) 2010-07-23
KR20070086074A (ko) 2007-08-27
WO2006063128A2 (fr) 2006-06-15
KR100890410B1 (ko) 2009-03-26
US20120309835A1 (en) 2012-12-06
AU2007229394B9 (en) 2010-02-18
US20120202885A1 (en) 2012-08-09
EP1827407A2 (fr) 2007-09-05
MX2007006245A (es) 2007-07-25
GB0525041D0 (en) 2006-01-18
EA011154B1 (ru) 2009-02-27
WO2006063128A3 (fr) 2006-08-17
AU2010200842A1 (en) 2010-04-01
NZ561148A (en) 2008-12-24
EP2289500A1 (fr) 2011-03-02
CA2584845A1 (fr) 2006-06-15
KR20070102591A (ko) 2007-10-18
LV13666B (en) 2008-07-20
JP2012097083A (ja) 2012-05-24
IL182837A0 (en) 2008-04-13
CN101129344A (zh) 2008-02-27
NO20075018L (no) 2007-09-06
BRPI0518616A (pt) 2008-01-15
GB2421433A (en) 2006-06-28
AU2007229394B2 (en) 2009-12-10
GB2421433B (en) 2008-01-02
JP2008523080A (ja) 2008-07-03
EA200701218A1 (ru) 2007-10-26
JP4178281B2 (ja) 2008-11-12
AU2005314039A1 (en) 2006-06-15
IL185761A0 (en) 2008-01-20
JP2008179648A (ja) 2008-08-07
EP1827407A4 (fr) 2008-05-21
BRPI0520207A2 (pt) 2012-09-25
GEP20094644B (en) 2009-03-10
AU2007229394A1 (en) 2007-11-08
CA2638753A1 (fr) 2006-06-15
EA010827B1 (ru) 2008-12-30
CN101072555A (zh) 2007-11-14
CN101072555B (zh) 2011-06-29
NZ554734A (en) 2009-03-31

Similar Documents

Publication Publication Date Title
NO20073510L (no) Metoder, bestemmelser og preparater for behandling av retinolrelaterte sykdommer
NO20080718L (no) Preparat for behandling av oftalmiske lidelser via serumretinol, serumretinol-bindingsprotein (RBP) og/eller serumretinol-RBP-modulering
BRPI0514395A (pt) uso terapêutico de inibidores de rtp801
WO2007047207A3 (fr) Inhibiteurs de la proteine activant la 5-lipoxygenase (flap)
NO20054292L (no) Fremgangsmate for behandling av smerte ved administrering av en nervevekstfaktorantagonist og NSAID og preparat inneholdende dette
WO2007056021A3 (fr) Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap)
WO2007053189A3 (fr) Compositions et méthodes pour altérer une fonction immunitaire
NO20083324L (no) Multisykliske aminosyrederivater og anvendelse derav
WO2007056220A3 (fr) Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap)
WO2007084684A3 (fr) Utilisations therapeutiques d’inhibiteurs de rtp801
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
WO2006052860A3 (fr) Modulateurs de la formation d'un complexe transthyretine (ttr)-proteine de liaison retinol-retinol (rbp)
EA201892189A1 (ru) Способы лечения витамином d
WO2007046083A3 (fr) Compositions pour le traitement de maladies oculaires
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
WO2007056301A3 (fr) Thérapie avec un anticorps pour le traitement de maladies associées à l'intolérance au gluten
WO2022026592A3 (fr) Molécules d'anticorps contre le coronavirus et leurs utilisations
WO2021074786A3 (fr) Compositions non hémolytiques et procédés d'utilisation pour la guérison d'une maladie provoquant des constituants toxiques dans le sang
MX2011005845A (es) Metodos, analisis y composiciones para tratar enfermedades relacionadas con retinol.
WO2006078336A3 (fr) Compositions et methodes permettant de traiter et de prevenir des maladies hyperproliferatives
NO20051159L (no) Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein
HRP20050580B1 (hr) Sinergistiäśki uäśinak kombinacije roflumilasta i (r,r)-formoterola
WO2006055404A3 (fr) Composes pour cibler des mecanismes impliques dans la progression de l'avc
WO2006031930A3 (fr) Modulation de l'activite de l'xbp-1 pour le traitement de troubles metaboliques
EA202191927A1 (ru) Модуляторы gpr35

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application